… severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) … the high vaccine coverage,
the incidence of SARS-CoV-2 … effectiveness of the BNT162b2 vaccine against SARS-CoV-2 …

… coronavirus 2 (SARS-CoV-2) test results after inoculation with the BNT162b2 messenger
RNA vaccine, we … 12–37 d after the first dose of vaccine. These reduced viral loads hint at a …

… of one dose of BNT162b2 vaccine in reducing infection with SARS-CoV-2 in real-world …
incidence of SARS-CoV-2 infection among individuals who received BNT162b2 vaccine will …

… Although the effectiveness of the vaccine against severe disease, hospitalization, and death
… for a third vaccine dose. Therefore, we administered a third 30-μg BNT162b2 dose 7.9 to 8.8 …

… The purpose of this study was to assess the association between receipt of a BNT162b2
mRNA vaccine and incidence of SARS-CoV-2 infection among pregnant women. …

… on vaccine efficacy in preventing asymptomatic SARS-CoV-2 infection are scarce, and our
results of rate reductions in SARS-CoV-… and sampling of vaccinated people and unvaccinated …

… with previous SARS-CoV-2 infection generate strong humoral and cellular responses to one
dose of BNT162b2 vaccine, with evidence of high titres of in-vitro live virus neutralisation. In …

… The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed …
live SARS-CoV-2. These data suggest that three doses of the mRNA vaccine BNT162b2 may …

… In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan … vaccinated
in a previously reported trial with the messenger RNA–based COVID-19 vaccine BNT162b2. …

… of the Pfizer-BioNTech BNT162b2 vaccine, we found a significantly (P<0.001) higher risk
of SARSCoV-2 infection with time elapsed since the second vaccine dose, after the initial 90 …